Documentos relacionados

1. Reacciones adversas relacionadas con endotoxinas bacterianas recibidas por el Sistema Nacional de Farmacovigilancia (2006-2017)
2. Using real-world evidence for pharmacovigilance and drug safety-related decision making by a resource-limited health authority: 10 years of experience in Taiwan.
3. Drug safety in multiple sclerosis: From reporting to signal detection and benefit-risk management.
4. Current career situations of Chinese pharmacovigilance professionals working for pharmaceutical companies: an exploratory survey.
5. A Proficient Spelling Analysis Method Applied to a Pharmacovigilance Task.
6. Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis.
7. Evaluación del perfil de seguridad del medicamento lopinavir/ritonavir (Lpv/r) en los pacientes sospechosos o confirmados por COVID-19
8. Hospital databases for the identification of adverse drug reactions: A 2-year multicentre study in 9 French general hospitals.
9. Provision and Characterization of a Corpus for Pharmaceutical, Biomedical Named Entity Recognition for Pharmacovigilance: Evaluation of Language Registers and Training Data Sufficiency.
10. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease.